Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Jabbour, Serge

< Back

Profile

saj102

Serge A. Jabbour, DM, FACP, FACE

Contact Dr. Jabbour

Walnut Towers
211 S. Ninth Street, Suite 600
Philadelphia, PA 19107

(215) 955-1925
(215) 928-3160 fax

Medical School

St. Joseph's University, Beirut, Lebanon - 1993

Residency

Cooper Medical Center, Camden NJ

Fellowship

Thomas Jefferson University Hospital

Board Certification

Internal Medicine
Endocrinology, Diabetes & Metabolism

Hospital Appointment

Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital

Awards & Honors

Philadelphia Magazine's Top Docs 2012, 2011

Publications

Most Recent Peer-Reviewed Publications

  1. Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease (Diabetes Therapy, (2020), 11, 7, (1467-1480), 10.1007/s13300-020-00815-z)
  2. Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION-8 study: A multicenter, double-blind, phase 3, randomized controlled trial
  3. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
  4. Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial
  5. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
  6. Scleromyxedema in a patient with thyroid disease: An atypical case or a case for revised criteria?
  7. Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study
  8. Dapagliflozin plus saxagliptin add-on therapy compared with insulin in patients with type 2 diabetes poorly controlled by metformin with or without sulfonylurea therapy: A randomized clinical trial
  9. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
  10. Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome
  11. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients withtype2diabetesinadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial
  12. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial
  13. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study
  14. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial
  15. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study
  16. Evaluation of an ongoing diabetes group medical visit in a family medicine practice
  17. Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014
  18. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials
  19. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes a randomized clinical trial
  20. Durability of response to dapagliflozin: a review of long-term efficacy and safety
  21. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
  22. Erratum to: Musculoskeletal manifestations of primary hyperparathyroidism (Clinical Rheumatology, (2016), 35, 12, (3081-3087), 10.1007/s10067-016-3450-3)
  23. Endocrinologic emergencies in dermatology
  24. Serum fructosamine: A simple and inexpensive test for assessing preoperative glycemic control
  25. Diagnosis and management of thyroid lymphoma